Skip to main content
Chemomab Therapeutics Ltd. logo

Chemomab Therapeutics Ltd. — Investor Relations & Filings

Ticker · CMMB ISIN · US16385C1045 US Manufacturing
Open in API
Filings indexed 332 across all filing types
Latest filing 2021-03-19 Audit Report / Informat…
Country US United States of America
Listing US CMMB

About Chemomab Therapeutics Ltd.

https://www.chemomab.com/

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company developing therapeutics for fibro-inflammatory diseases with high unmet medical needs. The company's scientific platform is based on the discovery of the soluble protein CCL24's central role in driving the cycle of fibrosis and inflammation. Its lead product candidate, nebokitug (CM-101), is a first-in-class monoclonal antibody designed to neutralize CCL24, thereby interfering with the primary pathways that promote these conditions. Nebokitug has demonstrated disease-modifying potential in multiple clinical trials and has received Orphan Drug and Fast Track designations from the U.S. FDA for the treatment of primary sclerosing cholangitis (PSC). Following positive Phase 2 results, the company is preparing for a potential Phase 3 trial for nebokitug in PSC.

Recent filings

Filing Released Lang Actions
FORM 8-K/A
Audit Report / Information Classification · 95% confidence The document is a Form 8-K/A filed with the SEC, which is an amendment to a previously filed Form 8-K. It discloses the closing of a merger transaction and includes the audited financial statements of Chemomab Ltd. as of December 31, 2020. The document is not a full annual report but an amendment to a current report providing financial statements related to a merger. The presence of audited financial statements attached to a Form 8-K/A related to a merger transaction aligns with the category of Audit Report / Information (AR), as it provides standalone audited financial statements required for the merger disclosure. The document is not an Annual Report (10-K), nor is it a simple announcement or certification. Therefore, the best classification is AR with high confidence.
2021-03-19 English
Director's Dealing 2021
Director's Dealing
2021-03-18 English
FORM 4 SUBMISSION
Director's Dealing
2021-03-18 English
FORM 3 SUBMISSION
Director's Dealing
2021-03-18 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes detailed information about a merger transaction, a private placement financing, changes in share capital, name change, and changes in the board of directors. It references the completion of a merger, issuance of shares, and other corporate actions. The document is not a full annual or quarterly report, nor is it a transcript or presentation. It is a regulatory filing reporting material corporate events and transactions. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it contains detailed event disclosures typical of an 8-K filing, confirming the classification with high confidence.
2021-03-16 English
FORM 4 SUBMISSION
Director's Dealing
2021-03-12 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.